Description:

CALGB: 80802 Adverse Event (AE) Form NCT01015833 Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=741A9174-BBAD-70FC-E040-BB89AD436A0F

Link:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=741A9174-BBAD-70FC-E040-BB89AD436A0F
Keywords:
  1. 9/19/12 9/19/12 -
  2. 1/9/15 1/9/15 - Martin Dugas
  3. 1/9/15 1/9/15 - Martin Dugas
  4. 7/8/15 7/8/15 -
Uploaded on:

July 8, 2015

DOI:
To request one please log in.
License :
Creative Commons BY-NC 3.0 Legacy
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

CALGB: 80802 Adverse Event (AE) Form NCT01015833

If data are amended, circle amended items and check the "Yes" box. If submitting by mail, retain a copy for your records.

Header
Are data amended
Patient demographics
Adverse Event Expedited Reporting System filed?
Has an AdEERS been filed (with Central Office based on an event reported below)
Expected Adverse Events
CTC AE Attribution Code (^2)
CTC AE Attribution Code (^2)

Similar models

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial